Promoting generous support and an ethical relationship
The Canadian Hemophilia Society is committed to improve the health and quality of life of all people with inherited bleeding disorders and ultimately to find a cure.
Working together with the corporate sector in Canada helps the Canadian Hemophilia Society (CHS) accomplish its mission and vision by extending our reach and reinforcing our messages. We seek contributions from like-minded corporations which support the CHS mission and vision, and which want to participate on an annual basis in providing support to general operational, research and program development initiatives that further the work of the CHS. Contributions are accepted from corporations and from corporate foundations, employee fund programs and employee generated activities.
The National Corporate Giving Program was created with a desire to…
– be open and transparent with our members, our sponsors, other stakeholders and with the public
– publicly recognize the contributions of our sponsors to the bleeding disorder community
– treat all our sponsors fairly
– maintain the independence of our organization in representing the needs of people with bleeding disorders.
Bayer is a global enterprise focused on the life science businesses of pharmaceuticals, consumer health and crop science. For more than 150 years, Bayer has been committed to creating a better life for all through science. Bayer Inc. is the Canadian subsidiary of Bayer AG and counts more than 1,360 employees across the country.
Bayer is one of the world’s main suppliers of products to treat hemophilia A. We are dedicated to helping patients with hemophilia through the advancement of recombinant factor VIII (rFVIII) therapeutic options and the development of innovative technologies, including antibody technology, gene therapy and gene editing. Together, these compounds reflect our commitment to research and development with the aim of reducing burden of treatment and improving the quality of life for people with hemophilia.
Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines, vaccines, and consumer health products. Every day, Pfizer Canada employees work to bring therapies to patients that significantly improve their lives. In 2010, Pfizer solidified its commitment to rare diseases by establishing a dedicated Rare Disease team, of which hemophilia and other bleeding disorders are a primary area of focus.
In Canada, we have worked alongside the hemophilia community for over 22 years, and have created a strong stakeholder collaboration with the Canadian Hemophilia Society (CHS), the Association of Hemophilia Clinic Directors of Canada (AHCDC) and other professional associations committed to the care of patients with hemophilia.
Novo Nordisk is committed to addressing the unmet needs in Hemophilia care. We work towards a future where everyone with Hemophilia is diagnosed and can live a life with as few limitations as possible. We offer a broad and innovative range of products and have a rich development pipeline to ensure we are in the forefront of finding the next generation of medicines.
Together with our partners, we work to advocate for, and create better access to, diagnosis and multidisciplinary care. We aim for better joint health and mobility including a strong focus on well-being for people living with hemophilia.